Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients

Acta Oncol. 2008;47(1):104-9. doi: 10.1080/02841860701472470.

Abstract

Metronomic low-dose chemotherapy regimen was found to have an antiangiogenic effect in tumors. However, its effect on levels of circulating pro-angiogenic and anti-angiogenic factors is not fully explored.

Materials and methods: The levels of both VEGF and PDGF-BB were measured in three time points, in the serum of 32 rectal carcinoma patients receiving daily reduced-dose/continuous capecitabine in combination with preoperative pelvic irradiation.

Results: We found a significant decrease in VEGF and PDGF-BB serum levels during the combination treatment (p < 0.0001), followed by an increase in the successive rest-period (p < 0.0001). In addition, substantial changes in platelets counts were observed during treatment in correlation with the changes of VEGF and PDGF-BB serum levels.

Discussion: These results suggest that combined chemo-irradiation affect levels of pro-angiogenic factors during treatment, and may reflect an anti-angiogenic window induced during this treatment. The potential implications of this inducible phenomenon, including a possible clinical benefit from the administration of long lasting metronomic chemotherapy immediately following combined chemo-irradiation, would warrant further investigation.

Publication types

  • Comparative Study

MeSH terms

  • Antimetabolites, Antineoplastic / administration & dosage
  • Antimetabolites, Antineoplastic / therapeutic use*
  • Becaplermin
  • Capecitabine
  • Carcinoma / blood
  • Carcinoma / drug therapy*
  • Carcinoma / physiopathology
  • Carcinoma / radiotherapy
  • Combined Modality Therapy
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / therapeutic use
  • Fluorouracil / administration & dosage
  • Fluorouracil / analogs & derivatives*
  • Fluorouracil / therapeutic use
  • Humans
  • Neoadjuvant Therapy
  • Neovascularization, Pathologic
  • Pelvis / radiation effects*
  • Platelet-Derived Growth Factor / drug effects
  • Platelet-Derived Growth Factor / metabolism*
  • Platelet-Derived Growth Factor / radiation effects
  • Proto-Oncogene Proteins c-sis
  • Rectal Neoplasms / blood
  • Rectal Neoplasms / drug therapy*
  • Rectal Neoplasms / physiopathology
  • Rectal Neoplasms / radiotherapy
  • Statistics as Topic
  • Vascular Endothelial Growth Factor A / blood*
  • Vascular Endothelial Growth Factor A / drug effects
  • Vascular Endothelial Growth Factor A / radiation effects

Substances

  • Antimetabolites, Antineoplastic
  • Platelet-Derived Growth Factor
  • Proto-Oncogene Proteins c-sis
  • Vascular Endothelial Growth Factor A
  • Deoxycytidine
  • Becaplermin
  • Capecitabine
  • Fluorouracil